Table of Content

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary and Secondary Sources
2.2. Quantitative Research
2.2.1. Primary and Secondary Sources
2.3. Breakdown of Primary Research Respondents
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents, By Industry Participants
2.5. Key Questionnaire asked during Primary Interviews
2.6. Key Primary Responses
2.7. Market Size Estimation
2.8. Assumption for the Study
2.9. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Antibody Drug Conjugate Market – Industry Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.2.4. Challenges
4.3. Regulatory Framework
4.4. Antibody Drug Conjugates Mechanism of Action
4.5. Porter’s Five Forces Analysis

5. Global Antibody Drug Conjugate Market Overview
5.1. Market Estimates & Forecast by Value, 2017-2027
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Type
5.2.1.1. Cleavable Linker
5.2.1.2. Non-cleavable Linker
5.2.2. By Application
5.2.2.1. Blood Cancer
5.2.2.1.1. Leukemia
5.2.2.1.2. Multiple Myeloma
5.2.2.1.3. Lymphoma
5.2.2.2. Breast Cancer
5.2.2.3. Urothelial Cancer & Bladder Cancer
5.2.2.4. Others
5.2.3. By End Users
5.2.3.1. Research Institutes
5.2.3.2. Biotechnology Companies
5.2.3.3. Hospitals
5.2.3.4. Clinics
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. The Asia-Pacific (APAC)
5.2.4.4. Latin America (LATAM)
5.2.4.5. The Middle-East & Africa (MEA)

6. North America Antibody Drug Conjugate Market Overview
6.1. Market Size and Forecast
6.1.1. By Value (USD Million), 2017-2027
6.2. Market Share and Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By End Users
6.2.4. By Country
6.2.4.1. U.S.
6.2.4.2. Canada

7. Europe Antibody Drug Conjugate Market Overview
7.1. Market Size and Forecast
7.1.1. By Value (USD Million), 2017-2027
7.2. Market Share and Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By End Users
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. U.K.
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Rest of Europe

8. Asia Pacific Antibody Drug Conjugate Market Overview
8.1. Market Size and Forecast
8.1.1. By Value (USD Million), 2017-2027
8.2. Market Share and Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By End Users
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. South Korea
8.2.4.5. Rest of Asia-Pacific

9. Latin America Antibody Drug Conjugate Market Overview
9.1. Market Size and Forecast
9.1.1. By Value (USD Million), 2017-2027
9.2. Market Share and Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By End Users
9.2.4. By Country
9.2.4.1. Argentina
9.2.4.2. Brazil
9.2.4.3. Rest of LATAM

10. Middle East & Africa Antibody Drug Conjugate Market Overview
10.1. Market Size and Forecast
10.1.1. By Value (USD Million), 2017-2027
10.2. Market Share and Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By End Users
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of Middle East & Africa

11. List of Antibody Drug Conjugates Patent Landscape

12. Antibody Drug Conjugates Pipeline Analysis

13. Competitive Landscape
13.1.1. List of Key Producers and Their Offerings
13.1.2. Market Share / Ranking Analysis (2020)
13.1.3. Competitive Benchmarking, By Operating Parameters
13.1.4. Antibody-Drug Conjugate Licensing and Merger and Acquisition (M&A) Deals

14. Impact of COVID-19 Across Industry

15. Company Profiles (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
15.1. Takeda Pharmaceutical Company Ltd.
15.2. F. Hoffmann-La Roche AG
15.3. Pfizer, Inc.
15.4. AstraZeneca
15.5. Gilead Sciences, Inc.
15.6. Astellas Pharma
15.7. Seagen, Inc.
15.8. Daiichi Sankyo Company Ltd.
15.9. GlaxoSmithKline Plc
15.10. Genentech Inc.

16. Key Strategic Recommendations
* Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

Fig 1: Global ADC Market Segmentation
Fig 2: Global ADC Market Size (USD Million)
Fig 3: Global ADC Market, By Type (in %), 2020
Fig 4: Global ADC Market: Industry Value Chain
Fig 5: Global ADC Market: History of ADC development
Fig 6: Global ADC Market: Mechanism of Action
Fig 7: Porters Five Forces Analysis
Fig 8: Global ADC Market Size, By Value (USD Million), 2017-2027
Fig 9: Global ADC Market Share (%), By Type, By Value, 2017-2027
Fig 10: Global ADC Market Share (%), By Application, By Value, 2017-2027
Fig 11: Estimated Number of New Cases in 2020, Worldwide
Fig 12: Global ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027
Fig 13: Global ADC Market Share (%), By End User, By Value, 2017-2027
Fig 14: Global ADC Market Share (%), By Region, By Value, 2017-2027
Fig 15: North America ADC Market Size, By Value (USD Million), 2017-2027
Fig 16: North America ADC Market Share (%), By Type, By Value, 2017-2027
Fig 17: North America ADC Market Share (%), By Application, By Value, 2017-2027
Fig 18: North America ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027
Fig 19: North America ADC Market Share (%), By End User, By Value, 2017-2027
Fig 20: North America ADC Market Share (%), By Region, By Value, 2017-2027
Fig 21: Europe ADC Market Size, By Value (USD Million), 2017-2027
Fig 22: Europe ADC Market Share (%), By Type, By Value, 2017-2027
Fig 23: Europe ADC Market Share (%), By Application, By Value, 2017-2027
Fig 24: Europe ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027
Fig 25: Europe ADC Market Share (%), By End User, By Value, 2017-2027
Fig 26: Europe ADC Market Share (%), By Region, By Value, 2017-2027
Fig 27: Asia-Pacific ADC Market Size, By Value (USD Million), 2017-2027
Fig 28: Asia-Pacific ADC Market Share (%), By Type, By Value, 2017-2027
Fig 29: Asia-Pacific ADC Market Share (%), By Application, By Value, 2017-2027
Fig 30: Asia-Pacific ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027
Fig 31: Asia-Pacific ADC Market Share (%), By End User, By Value, 2017-2027
Fig 32: Asia-Pacific ADC Market Share (%), By Region, By Value, 2017-2027
Fig 33: Latin America ADC Market Size, By Value (USD Million), 2017-2027
Fig 34: Latin America ADC Market Share (%), By Type, By Value, 2017-2027
Fig 35: Latin America ADC Market Share (%), By Application, By Value, 2017-2027
Fig 36: Latin America ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027
Fig 37: Latin America ADC Market Share (%), By End User, By Value, 2017-2027
Fig 38: Latin America ADC Market Share (%), By Region, By Value, 2017-2027
Fig 39: Middle East & Africa ADC Market Size, By Value (USD Million), 2017-2027
Fig 40: Middle East & Africa ADC Market Share (%), By Type, By Value, 2017-2027
Fig 41: Middle East & Africa ADC Market Share (%), By Application, By Value, 2017-2027
Fig 42: Middle East & Africa ADC Market Share (%), By Application, By Blood Cancer, By Value, 2017-2027
Fig 43: Middle East & Africa ADC Market Share (%), By End User, By Value, 2017-2027
Fig 44: Middle East & Africa ADC Market Share (%), By Region, By Value, 2017-2027
Fig 45: Global ADC Market: Leading Companies
Fig 46: Global ADC Market: Market Share Analysis, 2020

List of Tables

Table 1: Percentage of people across age intervals with risk of developing cancer, United States, 2015-2017
Table 2: Key ADC parameters that require optimization for clinical efficacy
Table 3: Global ADC Market Size (USD Million), By Type, By Value, 2017-2027
Table 4: Global ADC Market Size (USD Million), By Application, By Value, 2017-2027
Table 5: Global ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027
Table 6: Global ADC Market Size (USD Million), By End User, By Value, 2017-2027
Table 7: Global ADC Market Size (USD Million), By Region, By Value, 2017-2027
Table 8: North America ADC Market Size (USD Million), By Type, By Value, 2017-2027
Table 9: North America ADC Market Size (USD Million), By Application, By Value, 2017-2027
Table 10: North America ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027
Table 11: North America ADC Market Size (USD Million), By End User, By Value, 2017-2027
Table 12: North America ADC Market Size (USD Million), By Region, By Value, 2017-2027
Table 13: Europe ADC Market Size (USD Million), By Type, By Value, 2017-2027
Table 14: Europe ADC Market Size (USD Million), By Application, By Value, 2017-2027
Table 15: Europe ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027
Table 16: Europe ADC Market Size (USD Million), By End User, By Value, 2017-2027
Table 17: Europe ADC Market Size (USD Million), By Region, By Value, 2017-2027
Table 18: Asia-Pacific ADC Market Size (USD Million), By Type, By Value, 2017-2027
Table 19: Asia-Pacific ADC Market Size (USD Million), By Application, By Value, 2017-2027
Table 20: Asia-Pacific ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027
Table 21: Asia-Pacific ADC Market Size (USD Million), By End User, By Value, 2017-2027
Table 22: Asia-Pacific ADC Market Size (USD Million), By Region, By Value, 2017-2027
Table 23: Latin America ADC Market Size (USD Million), By Type, By Value, 2017-2027
Table 24: Latin America ADC Market Size (USD Million), By Application, By Value, 2017-2027
Table 25: Latin America ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027
Table 26: Latin America ADC Market Size (USD Million), By End User, By Value, 2017-2027
Table 27: Latin America ADC Market Size (USD Million), By Region, By Value, 2017-2027
Table 28: Middle East & Africa ADC Market Size (USD Million), By Type, By Value, 2017-2027
Table 29: Middle East & Africa ADC Market Size (USD Million), By Application, By Value, 2017-2027
Table 30: Middle East & Africa ADC Market Size (USD Million), By Application, By Blood Cancer, By Value, 2017-2027
Table 31: Middle East & Africa ADC Market Size (USD Million), By End User, By Value, 2017-2027
Table 32: Middle East & Africa ADC Market Size (USD Million), By Region, By Value, 2017-2027
Table 33: List of Antibody Drug Conjugates Patent
Table 34: List of Antibody Drug Conjugates Approved by FDA
Table 35: List of Antibody Drug Conjugates In Clinical trials
Table 36: ADC clinical trials in Recruiting Status
Table 37: List of ADC in Phase 1 Clinical Trials
Table 38: List of ADC in Phase 2 Clinical Trials
Table 39: List of ADC in Phase 3 Clinical Trials
Table 40: List of Key Players and Their Offerings
Table 41: Competitive Benchmarking, by Operating Parameters
Table 42: Antibody-Drug Conjugate Licensing and Merger and Acquisition (M&A) Deals.
Table 43: Takeda Pharmaceutical Company Limited Business Overview
Table 44: Takeda Pharmaceutical Company Limited Financial Analysis (USD Million)
Table 45: F. Hoffmann-La Roche AG Business Overview
Table 46: F. Hoffmann-La Roche AG Financial Analysis (USD Million)
Table 47: Pfizer Inc. Company Overview
Table 48: Pfizer Inc. Financial Analysis (USD Millions)
Table 49: AstraZeneca plc Company Overview
Table 50: AstraZeneca plc Financial Analysis (USD Millions)
Table 51: GiLead Sciences Inc. Business Overview
Table 52: GiLead Sciences Inc. Financial Analysis (USD Million)
Table 53: Astellas Pharma Inc. Business Overview
Table 54: Astellas Pharma Inc. Financial Analysis
Table 55: Seagen Inc. Business Overview
Table 56: Seagen Inc. Financial Analysis (USD Million)
Table 57: Daiichi Sankyo Company Ltd. Business Overview
Table 58: Daiichi Sankyo Company Ltd. Financial Analysis (USD Million)
Table 59: GlaxoSmithKline Plc. Limited Business Overview
Table 60: GlaxoSmithKline Plc. Financial Analysis (USD Million)
Table 61: Genentech, Inc. Business Overview
Table 62: F. Hoffmann-La Roche AG Financial Analysis (USD Million)